AI and the rise of blood-based biomarkers heralds new era for neurological diagnostics

Advances in blood-based biomarkers are transforming early and accurate Alzheimer’s disease detection, offering less invasive, cost-effective alternatives to traditional diagnostic methods. Quanterix, a company working at the very frontiers of neurology, is pioneering some of these innovations, integrating novel assays and partnerships to improve diagnostic precision and clinical adoption. In this exclusive SelectScience^® interview, we speak to Lindsey Mette, Director of Medical Affairs at Quanterix to learn more. 

Quanterix has been at the forefront of plasma-based biomarker development, including p-Tau 217 and BD-Tau. What makes these markers so promising for early and accurate Alzheimer’s detection?

Read the full coverage in SelectScience →